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Abstract
The emergence and spread of antimicrobial resistance is one of the major global issues currently threatening the health and wealth
of nations, with effective guidelines and intervention strategies urgently required. Such guidelines and interventions should
ideally be targeted at individuals, communities, and nations, requiring international coordination for maximum effect. In this
respect, the European Joint Programming Initiative on Antimicrobial Resistance Transnational Working Group ‘Antimicrobial
Resistance - Rapid Diagnostic Tests’ (JPIAMR AMR-RDT) is proposing to consider a ‘mix-and-match’ package for the imple-
mentation of point-of-care testing (PoCT), which is described in this publication. The working group was established with the
remit of identifying barriers and solutions to the development and implementation of rapid infectious disease PoCT for combatting
the global spread of antimicrobial resistance. It constitutes a multi-sectoral collaboration between medical, technological, and
industrial opinion leaders involved in in vitro diagnostics development, medical microbiology, and clinical infectious diseases.
The mix-and-match implementation package is designed to encourage the implementation of rapid infectious disease and antimi-
crobial resistance PoCT in transnational medical environments for use in the fight against increasing antimicrobial resistance.
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Introduction
Infectious diseases are one of the major contributors to
global morbidity and mortality. Further, the worldwide
spread of antimicrobial resistance means that this burden
is steadily increasing on a global scale, with the possibility
of untreatable infectious diseases being commonplace in
the near future [1]. Therefore, internationally coordinated
efforts are required to find, describe, and implement effec-
tive global healthcare strategies that will help combat the
threat of untreatable infectious diseases. In this respect,
the use of rapid infectious disease and antimicrobial resis-
tance point-of-care testing (PoCT) can be a key tool in
tackling the global burden of infectious disease and limit
the emergence and global spread of antimicrobial resistant
microorganisms. Further, in this publication, the authors
suggest that a ‘mix-and-match’ implementation package
is required in order to ensure the most effective and effi-
cient uptake and sustainability of rapid infectious disease
and antimicrobial resistance PoCT. The term ‘implemen-
tation’ as used in this publication relates to a number of
issues, including positively influencing clinical decision-
making processes, helping inform patients on how to
change their current behaviour, and taking note of
healthcare economics, whereby healthcare providers ex-
pect ‘value for money’ with respect to the detection and
treatment of infectious disease. A PoCT ‘mix-and-match
implementation package’ is defined as an implementation
package that offers a mixture of recommendations that can
be individually chosen to best match the needs of
healthcare providers, technology innovators, and the gen-
eral public, whilst helping to ensure the sustainability
(future-proofing) of rapid infectious disease and antimi-
crobial resistance PoCT.
Mix-and-match implementation package
for healthcare providers
Healthcare providers (including institutions such as hospitals,
clinics, and emergency rooms, as well as individual clinical
professionals such as doctors and nurses) are the primary po-
tential users of rapid infectious disease and antimicrobial re-
sistance PoCT, having direct access to patients and making
empirical decisions about the actual need for a particular di-
agnostic test.
Healthcare providers should be encouraged to establish
their own PoCT ‘working groups’, with the responsibility
for establishing a policy for the implementation of rapid in-
fectious disease and antimicrobial resistance PoCT into their
own particular healthcare setting [2]. These working groups
would also provide a focal point for the generation and distri-
bution of point-of-care educational material to medical
personnel. This will help to generate and maintain quality
standards, for example, compliance with ISO 22870 accredi-
tation. The working group should consider making a five
point pre-implementation plan: (1) surveying information on
perceived and real advantages and disadvantages of point-of-
care testing within their own institution; (2) proactively devel-
oping contacts with point-of-care device innovators, national
reimbursement groups, health technology assessment agen-
cies, etc.; (3) establishing selection criteria for PoCT devices;
(4) establishing institutional-wide management, quality con-
trol, and quality assurance procedures; and (5) promoting a
culture of cost-benefit and cost-effective analysis, thereby jus-
tifying the actual implementation of PoCT, including rapid
infectious disease and antimicrobial resistance PoCT. The
working group should ideally contain experts from the insti-
tution’s own diagnostic laboratories as well as representatives
of medical end-users, information technologists, pharmacists,
finance, and patients. Such PoCT working groups could also
act as a focal contact point for the introduction of expert
knowledge into community healthcare settings.
On the level of antibiotic use, antibiotic stewardship teams
(A-Teams) have been installed in American and European
hospitals and conventionally include experts in internal med-
icine, microbiology, pharmacy, quality management, paediat-
rics, and intensive care (as needed). These teams work closely
with infection prevention specialists in reducing the inappro-
priate use of antibiotics within medical institutions. However,
the added value of rapid infectious disease and antimicrobial
resistance PoCT to the antibiotic stewardship teams’ decision-
making processes may not be fully appreciated, even though
PoCT may provide an efficient approach for reducing the
evolution and spread of antimicrobial resistance [3]. Here,
further education of the respective stakeholders is required,
as well as the addition of qualified molecular diagnosticians
to the antibiotic stewardship teams. Once implemented, it
would be ideal if the A team were easily available, e.g. by
telephone, to answer questions from clinicians and nurses re-
garding AMR and AMR diagnostics.
At the individual level, the necessary implementation
changes required to make informed decisions on the use of
rapid infectious disease and antimicrobial resistance PoCTcan
be simply focused on increasing the current knowledge of
medical professionals about the subject via a wide variety of
sources, including scientific publications, which in general
will explain the lessons learnt from previously published in-
terventional studies. For example, Chandler et al. studied the
behavioural issues affecting the implementation of rapid ma-
laria testing and treatment in northern Tanzania [4]. The study
found that negative test results could lead to conflict situations
if a negative result meant that the health worker did not fulfil
the patient’s expectation of receiving malaria treatment.
Further, such malaria test negative patients may be prescribed
antibiotics leading to an increase in the untargeted use of
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antibiotics [5]. Similar issues were identified in a study of C-
reactive protein (CRP) testing for lower respiratory tract in-
fections in Europe. These issues could have been addressed by
implementing online behaviour change interventions with in-
structions, training, and patient resources [6].
In a recent publication, Klein et al. employed psychology
to investigate how the perceptions of clinicians influenced
their clinical decision-making process within emergency de-
partments [7]. Differences in the decision to prescribe antibi-
otics by emergency department clinicians could be related to
two possibly conflicting perceptions. These were ‘Why not
take a risk?’ and ‘Antibiotics may be harmful’. The results
reported in this study suggested that interventions to reduce
inappropriate prescribing should emphasise the possibility of
serious side effects when prescribing antibiotics. Rapid infec-
tious disease and antimicrobial resistance PoCT educational
campaigns could therefore emphasise that prescribing antibi-
otics also carries a risk to the patient. However, whether such
perceptions are common to physicians within different coun-
tries, cultures or educational levels remains to be determined.
Whatever the method used, perhaps the best approach to
successfully implementing such testing is to avoid the learning
or adoption of ‘bad behaviour’ in the first place. This process
is for example addressed by AMR DxC - The Antimicrobial
Resistance Challenge competition, an interdisciplinary initia-
tive whereby multi-disciplinary teams of young medical stu-
dents and early career scientists from different geographic
regions come together to discuss and work collaboratively
on medical diagnostic solutions. Cross-cutting interdisciplin-
ary discussions are key aspects of such programs, whereby
younger generations of clinicians, diagnostic innovators, so-
cial scientists, and device designers discuss and understand
the current challenges associated with the development and
implementation of rapid infectious disease PoCT to tackle
antimicrobial resistance [8].
Mix-and-match implementation package
for rapid infectious disease and antimicrobial
resistance PoCT innovators
PoCT innovators can play a major role in ensuring the suc-
cessful adoption of infectious disease testing. As an example,
there is a current emphasis on adapting and developing cutting
edge technologies for infectious disease diagnostics without
focusing on the actual clinical need for these technologies in
the detection of infectious diseases and antimicrobial resis-
tance. Therefore, innovators should establish bi-directional
communication channels with end-users and other stake-
holders. These groups should interact synergistically, forming
a positive feedback loop, whereby the changing needs of the
end-user generates adaptation in diagnostic device develop-
ment. One method could include the use of online or email-
based questionnaires containing targeted questions that are
designed to shape the desired current and future performance
characteristics and settings of the device, thereby contributing
to the creation of specific target product profiles (TPP).
However, ideally, a range of methods is required to compre-
hensively understand user participation, possibly including
interviews, observational studies, and focus group meetings
[9] For sustainability, rapid infectious disease and antimicro-
bial resistance PoCT innovators should obtain up-to-date in-
formation on infectious disease research and epidemiology via
regular visits to scientific conferences, accessing horizon
scanning reviews [10] or by asking for relevant information
from insurance companies, professional societies, patient as-
sociations, health technology assessment bodies, regulatory
bodies and global infectious disease alert systems such as
Promed (https://www.promedmail.org/).
Another large problem faced by innovators is the need for
strong evidence to confirm that their technologies can actually
improve current clinical practice, using evidence-based rather
than empirical medicine. In this context, evidence-based re-
lates to Bthe conscientious, explicit, and judicious use of cur-
rent best evidence in making decisions about the care of indi-
vidual patients^, and empirical to Bbased on, concerned with,
or verifiable by observation or experience rather than theory or
pure logic^ [11] (https://en.oxforddictionaries.com/definition/
empirical). The successful implementation of rapid infectious
disease and antimicrobial resistance PoCT will rely on
clinicians obtaining data from patient-centred studies that
compare and contrast the new diagnostic test with current gold
standard testing methods, considering inputs such as the costs
of training, devices, test kits, quality control, and assurance
schemes, as well as outputs such as reduced antibiotic pre-
scribing costs, shorter hospitalisation, reduced antimicrobial
resistance, and improved quality of life [12]. To generate these
data, clinical studies need to be performed and the results
published in scientific journals. Further, summaries or short
information leaflets could form part of sales and marketing
campaigns to build user awareness. That said, it is appreciated
by the JPIAMR AMR-RDT working group that establishing
and conducting these studies can be very expensive, especially
for innovators in small and medium-sized enterprises.
However, being trustworthy and open with consumers,
healthcare authorities, investors, and patients would help
avoid prominent crises, such as occurred with Theranos [13].
For further guidance, PoCT innovators should consult reg-
ulatory frameworks such as the latest In Vitro Diagnostic
Device Regulation (EU 2017/746) of the European Union
which also lays the legal framework for the European database
on medical devices (EUDAMED) which by 2020 will facili-
tate access to information on existing diagnostics (http://eur-
lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%
3A32017R0746). To succeed with the development of viable
products, innovators need to consider business-to-business
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implementation strategies. Ultimately, innovators need to be
able to invest in manufacturing facilities, salaries, marketing,
etc., and clinicians need to be able to use PoCT with confi-
dence of an improved health economic benefit.
A lack of standardised national and international reim-
bursement schemes is currently reducing the potential imple-
mentation and impact of PoCT. This effect is not only restrict-
ed to traditional healthcare settings, but also involves potential
new markets such as home-based care, telemedicine, and in-
home testing and monitoring, where some form of reimburse-
ment is essential [14]. In some countries, clinicians are funded
via a national healthcare service, which may be prepared to
pay for in-house medical testing, for example for PoCT per-
formed at a general practitioner’s office [15]. However,
though patient healthcare insurance may be available in some
countries, not everyone can afford to pay basic healthcare
insurance premiums, and a choice may have to be made be-
tween paying for a PoCT or simply buying antibiotics. In this
respect, evidence of added value is essential and innovators
could encourage the implementation of their diagnostics by
being flexible in their pricing strategy, for example, by basing
their prices on the number of tests sold. Also, cooperation with
product development partnerships and/or non-governmental
organisations are other possible options for promoting sales
and reimbursement, including for example the establish-
ment of ‘Diagnostic Market Stimulus Pots’ to ‘ensure a
market based revenue stream for developers’ [16]. In any
case, finding funding for healthcare validation studies is
one of the major challenges facing all developers of
healthcare diagnostics.
Gender and cultural issues may also play a major role in
preventing the implementation of PoCT due to the
stigmatisation of patients found to be infected with a particular
pathogen—not forgetting that stigmatisation could also be
based on a false positive test result. For example, a positive
human immunodeficiency virus, sexually transmitted disease,
Ebola, etc., test result may be utilised to justify existing prej-
udices or beliefs based on gender, sexual preference, or immi-
gration status [17]. Further, Borg identified behaviour charac-
teristics related to Bcultures that are low in uncertainty avoid-
ance and power distance, and high in individualism and
masculinity^ that could influence PoCT implementation strat-
egies [18]. Whilst it is not feasible for, or indeed the respon-
sibility of, diagnostics innovators to change an individual’s or
culture’s beliefs or prejudices, innovators must be sympathetic
and knowledgeable about their target population. In this re-
spect, one possible route for accessing potentially stigmatised
communities would be to approach the community via a
trusted intermediary, who may be a community opinion lead-
er, local tribal elder, or a religious leader.
If we consider the future expansion of healthcare, then it is
not unreasonable to assume that some form of PoCT will
eventually be routinely used by members of the public, via
pharmacies or at home, without the supervision of a medical
professional. To prevent confusion by the pharmacist or end-user,
as well as unnecessary visits to already overworked family doc-
tors, pharmacists, and emergency departments, PoCT innovators
should ideally establish telephone or internet hotlines that are
available to answer the questions of pharmacists or PoCT device
home-based users. These hotlines could potentially form addi-
tional arms of existingmedical information hotlines, for example
the UK NHS 111 service (www.nhs.uk/NHSEngland/
AboutNHSservices/Emergencyandurgentcareservices/Pages/
NHS-111.aspx). Further, by collecting data from such
services, hotline providers could generate essential
feedback to diagnostics innovators that could be used to
increase device performance or improve the simplicity of
instruction material supplied with the diagnostic. However, it
should be noted that performing PoCT at the pharmacy or at
home is a controversial issue. For example, a recent pharmacy
‘test and treat’ scheme for sore throat diagnosis in England
attracted some criticism regarding poor sensitivity and lack of
a full cost-effectiveness analysis [19]. Finally, diagnostics in-
novators should gain a deep understanding of the context and
views of potential end-users before product development pro-
gresses into a functional and marketable device, for example,
using established ‘user-centred’, ‘participatory design’, or
‘person-based’ approaches. Innovators should not simply fo-
cus on the development of ‘technology for technology’s sake’.
Just because a technology exists that could be adapted for
PoCT, does not mean to say that the technologywill ultimately
be successful as a healthcare diagnostic.
Mix-and-match implementation package
for the general public
Promoting change in the standard practice of clinical medicine
has traditionally been achieved by actively targeting clini-
cians, with the possible exception of vaccination campaigns
that are designed to encourage the general public to vaccinate
themselves and their children against a range of infectious
diseases. However, the realisation that the world is ap-
proaching an antimicrobial resistance catastrophe where clin-
ically relevant microorganisms are resistant to all available
antibiotics has led to global efforts to educate the general
public about the dangers of the misuse of antibiotics. These
educational efforts need to include information on the value of
PoCT in helping reduce untargeted antibiotic prescribing prac-
tices. In this respect, PoCT educational material/campaigns
could be generated that are aimed at the general public via
hospital and family doctor leaflets, radio/newspaper/TV ad-
vertisements, etc. Slogans adapted from existing infectious
disease diagnostic companies or new slogans such as ‘Lack
of a diagnostic result? Unnecessary antibiotics during the con-
sult!’ could be used. Additionally, the general public should be
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encouraged to think about the consequences of antibiotic pre-
scribing on themselves (for example the ‘collateral damage’
caused by antibiotics to the patient’s own protective mi-
crobiota) and on their own extended families and com-
munities (for example the threat of growing worldwide
antimicrobial resistance on communities in which their
family members live). Such educational material should
take into account the education level, geography, and
religious belief of the target audience.
Perhaps health warnings could be added to packets of an-
tibiotics that would indicate that antibiotics should ideally
only be taken after a positive (PoCT) test result has been
obtained [20]. Such warnings may help generate a mental link
between a lack of accurate diagnosis and the incorrect/over-
prescribing of antibiotics. Such a link could persuade patients
to discuss diagnostic issues with their clinician before receiv-
ing antibiotics. However, it should be noted that in order to be
effective, the content of such health warnings should address
the patients’ own beliefs, for example, a belief that they them-
selves are not at risk from antimicrobial resistant infections or
that their behaviour may not be contributing to the increase
and spread of antimicrobial resistance.
Mix-and-match implementation
considerations for long-term viability (future
proofing)
The long-term viability of PoCT may be affected by, for ex-
ample: (1) genomic mutations in pathogenic microorganisms;
(2) the emergence of new antimicrobial resistance traits; (3)
antigenic shifts related to the introduction of new vaccines; (4)
the spread of previously unknown pathogenic microorgan-
isms to humans and domesticated animals, and (5) the creation
of new ecological niches due to global climate change.
Therefore, regular adaptation of diagnostic devices (future
proofing) will be necessary to ensure that their added value
is actually sustainable. Accurately predicting the future is
always difficult, but armed with a few simple concepts
(described below), both innovators and end-users may be
able to adapt their current behaviour so as to plan for, and
reap, the potential rewards available from the long-term
viability of PoCT.
PoCT innovators and (inter)national health authorities
should be aware that decentralisation may bring with it new
(exploitable) possibilities. For example, the use of telemedi-
cine may facilitate the interpretation of results by clinicians far
away from the site where a patient is being tested, as well as
the ability to collect global infectious disease test results in real
time during disease outbreaks. However, these exploitable
possibilities bring with them potential problems such as pa-
tient authorisation, investment in large-scale data storage cen-
tres and management, data security, and ethical issues.
Smartphone ownership is ubiquitous and the rate of
smartphone ownership in emerging economies and develop-
ing countries has been increasing at an extraordinary rate. This
rise in the ownership of smartphones has been accompanied
by a rise in the development of both software and hardware
applications in the field of rapid PoCT diagnostics, for exam-
ple, the Colorimetrix app (portable spectrophotometer), the
smartphone ‘Olloclip’ lens (microscopy), and smartphone
‘Otoscope’ (ear infections). Additionally, large steps are being
made in the rapid nucleotide sequencing of pathogens using
portable devices, facilitating the generation of so-called
‘omics’-based data including genomics and transcriptomics
data (https://nanoporetech.com/). Further, although possible
discrepancies between genomic and phenotypic data
currently exist, future advances in the transcriptomic
sequencing of mRNA transcripts may provide the necessary
link between genomic data and phenotypic characteristics of
infectious disease pathogens [21].
As ‘omics-based’ data becomes more abundant, it is ex-
pected that machine learning (i.e. the ability of computers to
learn without being explicitly programmed to do a task), will
become increasingly relevant to behaviour change in clinical
settings. In this respect, clinical decision support systems
(CDSS) incorporated in, or connected to, PoCT diagnostics
may help clinicians to (1) distinguish between viral and bac-
terial infections; (2) assess regional and personalised antimi-
crobial resistance profiles; (3) improve antibiotic prescribing
practices, and (4) predict a patient’s response to treatment
[22]. However, the integration of machine learning into clin-
ical practice requires a combination of accuracy, predictive
power, and interpretability. This will require the establishment
of interdisciplinary expert panels and clinical trials, rather than
simply relying on computer technologists to write algorithms
and publish their results. That said, the importance of artificial
intelligence in the detection and validation of clinical bio-
markers in infectious disease diagnosis has been highlighted
by the winner of the XPRIZE (https://tricorder.xprize.org/
prizes/tricorder/articles/family-led-team-takes-top-prize-in-
qualcomm-tricor). The winner recently received $2·6 million
for an artificial intelligence-based engine ‘DxtER’, which con-
sists of Ba group of non-invasive sensors that are designed to
collect data about vital signs, body chemistry and biological
functions. This information is then synthesised in the device’s
diagnostic engine to make a quick and accurate assessment^.
This type of development points to a future where individ-
ual PoCT diagnostics may become redundant to new more
powerful diagnostics that are able to diagnose many dif-
ferent infectious and non-communicable diseases together
and potentially predict treatment outcomes in a more cost-
effective manner.
Decentralisation and the ability to transmit data over vast
distances, whilst simultaneously being able to link many thou-
sands of diagnostic devices with each other, could be
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profoundly advantageous for the health of citizens and na-
tions. The worldwide implementation and connectivity of
PoCT diagnostics could lead to advances in holistic healthcare
monitoring, with such devices regularly communicating with
each other—exchanging patient information, clinical histo-
ries, cardiology data, X-rays, tomography results, etc.
Additionally, by blending the results of such data with data
collected from environmental, ecological, meteorological,
and entomological sources, new multi-dimensional algo-
rithms could be developed for high-level predictive model-
ling of the origin and spread of existing and emerging in-
fectious diseases. Such global healthcare networks and algo-
rithms could also act as early warning systems for the rapid
detection of epidemics, allowing the targeted distribution of
healthcare resources to affected areas [23]. Examples include
(1) modelling and predicting the effect of global warming
and urbanisation on infectious diseases, such as the spread
of extensively drug-resistant tuberculosis in HIV popula-
tions; (2) monitoring the spread of mosquito borne diseases
from Africa into Europe; (3) determining the genotype of
currently circulating strains of influenza in their seasonal
progression around the world; and (4) monitoring the health
of migrant and refugee populations. To be feasible,
standardised data collection, databases, data exchange, pri-
vacy protocols, and cybersecurity issues will have to be
implemented, especially in an age of connectivity via the
Internet of Things. However, it should be noted that saving
costs on data security in an age of PoCT diagnostic connec-
tivity could potentially result in poorly protected devices
with vulnerabilities that leave them open to hacking and
malware (www.theregister.co.uk/2015/10/19/bods_brew_
ikettle_20_hack_plot_vulnerable_london_pots/).
The complex ‘mix and match’ implementation package is
shown in Fig. 1.
More Efficient and Sustainable Uptake of 
Rapid Infectious Disease Point-of-Care Testing
‘Mix and Match’ Implementation Package
• Establish Bi-Directional Communication Channels
• Provide Strong Evidence to Support New Diagnostics
• Develop Financial Reimbursement Strategies
• Be Aware of Stigmatisation
• Telephone/Internet Information for Pharmacy/Home Testing 
• No Technology for Technology's Sake
PoCT Innovators
• Prepare for Decentralisation
• Develop Clinical Decision Support Systems
• Multi-Parameter Diagnostics for ‘One Size Fits All’
• Strengthen Data Security e.g., the Internet of Things 
• Connectivity Allows Global Population Monitoring
Long-Term Viability (Future-Proofing)
v
Healthcare Providers
• Establish Point-of-Care Work Groups
• Contact the ‘A-Team’
• Consider Lessons Learnt
• Be Aware of Physicians’ Perceptions
• Address Implementation Issues Early
• Provide Education
v
General Public
• Targeted Education Campaigns
• Consider ‘Health Warnings’
Fig. 1 Complex ‘mix-and-match’
implementation package for the
successful implementation of
rapid infectious disease and
antimicrobial resistance point-of-
care testing. One barrier to the
successful uptake and sustain-
ability of rapid infectious disease
and antimicrobial resistance
point-of-care testing (PoCT) is the
need to take into account the long-
term viability, sustainability, and
durability of these diagnostics. In
this respect, the implementation
components in the figure may be
chosen using a ‘mix-and-match’
process to best suit individual
healthcare settings and/or indi-
vidual rapid infectious disease
and antimicrobial resistance
PoCT diagnostic operating char-
acteristics. ‘A-Team’ = Antibiotic
Stewardship Team. ‘Internet of
Things’ = the network of devices,
e.g. home appliances that contain
electronics and software which
allows these devices to connect,
interact, and exchange data
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Conclusions
Infectious diseases are one of the major contributors to global
morbidity and mortality. In this respect, the successful imple-
mentation of rapid PoCT into healthcare settings has the po-
tential to help slow down and prevent the global spread of
infectious diseases and antimicrobial resistances. This can be
achieved by better monitoring of infections and by facilitating
the accurate and targeted prescribing of antibiotics to those
patients who actually need them. However, it should be noted
that the successful implementation and long-term viability of
rapid infectious disease and antibiotic resistance PoCT is not
solely dependent on the development, sales, and marketing of
diagnostic devices. Instead, a more sophisticated and holistic
approach is required that takes the opinions and requirements
of end-users into account, whilst remaining technologically
flexible in order to meet the demands of future trends.
Consideration of the ‘mix-and-match’ implementation change
package described in this publication will help facilitate the
uptake and sustainability of PoCT diagnostics into healthcare
settings. Successful implementation will be a key step in re-
ducing the spread and development of antibiotic resistant in-
fections, helping improve global healthcare outcomes in terms
of patient morbidity and mortality.
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